Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives

References

• (RCC) RCis. Cancer i Sverige Registerdata över förekomst och dödlighet 1970-2017. 2020.
   Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Morton D, obotIFT I. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for Colon cancer. J Clin Oncol. 2019;37(15_suppl):3504–3504.
   Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516.
   PubMed Web of Science ®Google Scholar
• Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;2015(12):Cd011134.
   PubMedGoogle Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–618.
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006;55(6):848–855.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in Colon cancer. J Clin Oncol. 2010;28(20):3219–3226.
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for Colon cancer. N Engl J Med. 2003;349(3):247–257.
   PubMed Web of Science ®Google Scholar
• Cohen R, Taieb J, Fiskum J, et al. Microsatellite instability in patients with stage III Colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol. 2021;39(6):642–651.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bifulco C, Bindea G, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III Colon cancer. J Clin Oncol. 2020;38(31):3638–3651.
   PubMed Web of Science ®Google Scholar
• Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707–712.
   PubMedGoogle Scholar
• Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765.
   PubMed Web of Science ®Google Scholar
• Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131.
   PubMed Web of Science ®Google Scholar
• Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized Colon cancer. Ann Oncol. 2019;30(11):1804–1812.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon cancer. JAMA Oncol. 2019;5(12):1710.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II Colon cancer. Sci Transl Med. 2016;8(346):346ra92.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Cohen JD, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol. 2019;5(8):1118.
   PubMed Web of Science ®Google Scholar
• Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Ann Oncol. 2019;30:v867.
   Web of Science ®Google Scholar
• Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II Evaluation. https://ClinicalTrials.gov/show/NCT04089631.
   Google Scholar
• Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II. https://ClinicalTrials.gov/show/NCT04120701.
   Google Scholar
• Taïeb J, Benhaim L, Laurent Puig P, et al. Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: the CIRCULATE-PRODIGE 70 trial. Dig Liver Dis. 2020;52(7):730–733.
   PubMedGoogle Scholar
• Tracking mutations in cell free tumour DNA to predict relapse in early colorectal cancer. https://ClinicalTrials.gov/show/NCT04050345.
   Google Scholar
• Anandappa G, Starling N, Peckitt C, et al. TRACC: tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—a randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC). J Clin Oncol. 2020;38(15_suppl):TPS4120–TPS.
   Web of Science ®Google Scholar
• IMPROVE intervention trial implementing non-invasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer. https://ClinicalTrials.gov/show/NCT03748680.
   Google Scholar
• Nors J, Henriksen TV, Gotschalck KA, et al. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol. Acta Oncol. 2020;59(3):336–341.
   PubMed Web of Science ®Google Scholar
• Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: the PEGASUS trial. https://ClinicalTrials.gov/show/NCT04259944.
   Google Scholar
• Schraa SJ, van Rooijen KL, van der Kruijssen DEW, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II Colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020;20(1):790.
   PubMed Web of Science ®Google Scholar
• Circulating Tumour DNA (ctDNA) as a prognostic and predictive marker in colorectal cancer – a pilot study. https://ClinicalTrials.gov/show/NCT04726800.
   Google Scholar
• Parsons HA, Rhoades J, Reed SC, et al. Sensitive detection of minimal residual disease in patients treated for Early-Stage breast cancer. Clin Cancer Res. 2020;26(11):2556–2564.
   PubMed Web of Science ®Google Scholar
• Australian New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): NHMRC Clinical Trials Centre UoSA-. Circulating tumour DNA (ctDNA) analysis informing adjuvant chemotherapy in Stage II Colon Cancer. 2015 [updated 2015 Mar 13]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000381583
   Google Scholar
• Australian New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): NHMRC Clinical Trials Centre UoSA-. Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC-III): https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373948. 2017. [updated 2017 Nov 8].
   Google Scholar
• Australian New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): NHMRC Clinical Trials Centre UoSA-. Use of circulating tumour DNA (ctDNA) results to inform the decision for adjuvant chemotherapy in patients with locally advanced rectal cancer who have been treated with pre-operative chemo-radiation and surgery. http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617001560381. 2017. [updated 2017 Aug 19].
   Google Scholar
• Circulating tumor DNA testing in predicting treatment for patients with stage IIA colon cancer after surgery. https://ClinicalTrials.gov/show/NCT04068103.
   Google Scholar
• Dasari A. Circulating tumor DNA Alexandria: gastrointestinal cancers symposium. 2021. [cited 2021 Feb 16]. Available from: https://meetinglibrary.asco.org/record/193213/video.
   Google Scholar
• Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112(7):2915–2920.
   PubMed Web of Science ®Google Scholar
• Overman MJ. Discussion - oral abstract session: anal and colorectal cancer Alexandria: gastrointestinal cancers symposium. 2021. [cited 2021 Feb 10]. Available from: https://meetinglibrary.asco.org/record/194481/video.
   Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415.
   PubMed Web of Science ®Google Scholar
• Schmitt MW, Kennedy SR, Salk JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109(36):14508–14513.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368–16373.
   PubMed Web of Science ®Google Scholar
• Denis JA, Guillerm E, Coulet F, et al. The role of BEAMing and digital PCR for multiplexed analysis in molecular oncology in the era of Next-Generation sequencing. Mol Diagn Ther. 2017;21(6):587–600.
   PubMed Web of Science ®Google Scholar
• Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1–2):57–68.
   PubMed Web of Science ®Google Scholar
• Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–759.
   PubMed Web of Science ®Google Scholar
• Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579–583.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–530.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-Mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37(17):1460–1469.
   PubMed Web of Science ®Google Scholar
• Henriksen TV, Tarazona N, Reinert T, et al. Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. J Clin Oncol. 2021;39(3_suppl):11–11.
   Web of Science ®Google Scholar